________________________________________________________________________________________________________________________________

How to Ensure the Health of the Industry

Paul Pomerantz on strategic re-orientation of DIA, the world’s largest organisation of pharma professionals

November 2009. Paul Pomerantz incoming Global Executive Director of the Drug Information Association (DIA) describes his approach. He is discussing current weaknesses of the world’s largest organisation of pharma professionals and is offering an outlook on DIA’s future strategy in particular its lobbying role and challenges in Asia – exclusively for readers of B2Bioworld.

 

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 2 pages
- Includes detailed geographical breakdown of DIA’s membership and DIA Advisers 2009

Full Company License enquire here

Back to section

Related Editorial Articles

Pharma Boost for Red Cross/Red Crescent
- Community Disease Prevention Programme

BIO 2009 failed to mirror biotechnology markets worldwide

Improving the IP System on a global scale: A view from Japan
Sadao Nagaoka, Institute of Innovation Research, and Chief Policy Adviser to the Japanese Government

Merck Serono Manufacturing: We have biosimilars coming …

Roche Ethiopia: Build-up of an emerging market

Easier Access to Patent Claims Encoded in Chinese

Riding ahead demand in the trade fair industry
Jochen Köckler of Deutsche Messe AG about strategic assumptions and business in different parts of the world